When I describe the cancerous lump I found in my breast almost three Novembers ago, I explain that it felt like a hard, frozen green pea. The port used for chemotherapy infusions and sewn under the skin near my collarbone? It looked like a bottle cap popping up for all to see. My kids called it a stone. I had to numb my skin prior to treatments -- the needle inserted into the center of the port was just too big and painful. I slathered on my numbing lotion prior to each dose of drugs. Imagine the size of a quarter. I used twice this much. I was wimpy.

There's something about visual descriptions that help us remember some of the more important things in life. Here's a good one:

According to Jeffrey Dover, MD and associate clinical professor of dermatology at Yale School of Medicine, we must not skimp when we apply sunscreen. How do we know if we are cutting ourselves short? We should be using a shot-glass full of sun protection to cover our bodies. Anything less is not enough.

The world's largest drug maker -- Pfizer Inc. -- announced Monday it will cut 10,000 jobs and close at least five facilities due to fierce competition from generic drug makers. The goal, says Pfizer spokespeople, is to whittle away annual costs by $2 billion by the end of the year -- to combat the prediction that the company will lose 41 percent of its sales to generic drugs between 2010 and 2012.

Pfizer's other obstacles include expiring drug patents -- costing Pfizer about $14 billion in revenues between 2005 and 2007 -- as well as demands for lower prices by insurers and large purchasers, and repeated requests for evidence of products' worth.

The 10,000 layoffs amount to 10 percent of the company's global workforce and will take jobs from 2,200 United States employees. The company will cut 20 percent of its European sales force, will close three research sites in Michigan and two manufacturing plants in New York and Nebraska, and is considering selling a manufacturing site in Germany and closing two research sites in Japan and France. In the midst of all of this, the company will focus its efforts on transforming the way they do business.

"I believe we must transform the way we've done business in the past in order to be more successful in the future," said Jeffrey Kindler, CEO and chairman of Pfizer. " Incremental evolution is not enough. Fundamental change is imperative -- and it must happen now."

Pfizer's Monday announcement is the second declaration of budget cuts. A previous announcement has the company -- the maker of cancer drugs Aromasin, Ellence, Camptosar, and Sutent -- slashing costs by $4 billion a year until 2008.